Stellar Biotechnologies Presents Preclinical Poster on Clostridium Difficile Research at Society for Glycobiology Meeting

PORT HUENEME, CA--(Marketwired - Dec 4, 2015) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (NASDAQ: SBOT) (TSX VENTURE: KLH), announced today the presentation of a preclinical poster relating to its research on Clostridium difficile ("C. difficile"), at the Society for Glycobiology 2015 Annual Meeting, in San Francisco, California, December 1-4, 2015.

The poster, titled "Clostridium difficile Surface Polysaccharide-KLH Conjugate Vaccine Induced Th17-Featured Adaptive Immune Responses in Mice," was authored by Stellar Biotechnology scientist Shuguang Bi, Ph.D. The presentation reported data from Stellar's ongoing research into the potential development of C. difficile cell surface polysaccharide-KLH conjugate vaccines, or active immunotherapies, for the treatment of C. difficile infection.

The full poster can be viewed online here: Poster

C. difficile is a growing cause of morbidity and mortality in hospitalized patients, with the rate of U.S. cases at a record high. Although the C. difficile bacteria are normally present in the intestine, it can overgrow due to antibiotic use. The resulting infection causes severe diarrhea and life-threatening intestinal conditions, such as colitis.

The Society for Glycobiology is a nonprofit scholarly society devoted to the pursuit of knowledge of glycan structures and functions and to the sharing of that knowledge among scientists worldwide. The theme of the Society's 2015 Annual Meeting was "Glycobiology: Accelerating impact across the biomedical sciences."

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (NASDAQ: SBOT) (TSX VENTURE: KLH) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Visit www.stellarbiotech.com and the KLH knowledge base www.klhsite.org.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with governmental regulations; the timing of anticipated results; and other factors referenced in the Company's filings with securities regulators. For a discussion of further risks and uncertainties related to the Company's business, please refer to the Company's public company reports filed with the TSX Venture Exchange and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information contained in this press release.